Compare
Neuphoria Therapeutics Inc. vs Longeveron Inc. vs China SXT Pharmaceuticals, Inc. vs Vistagen Therapeutics, Inc.
| Latest fiscal year | Neuphoria Therapeutics Inc. NEUP | Longeveron Inc. LGVN | China SXT Pharmaceuticals, Inc. SXTC | Vistagen Therapeutics, Inc. VTGN |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2026-03-31 | 2026-03-31 |
| Revenue | $1.17M | $1.20M | $1.14M | $1.27M |
| Revenue growth (YoY) | -92.5% | -49.9% | -34.6% | +161.1% |
| Gross margin | n/a | 67.0% | 21.9% | n/a |
| Operating margin | n/m | n/m | -625.9% | n/m |
| Net margin | n/m | n/m | -545.2% | n/m |
| Net income | -$13.45M | -$22.70M | -$6.21M | -$69.69M |
| EPS (Diluted) | -$3.06 | -$1.29 | -$9.13 | -$1.83 |
| Operating cash flow | -$12.35M | -$18.64M | -$4.02M | -$66.44M |
| Free cash flow | n/a | -$18.89M | n/a | n/a |
| Cash & equivalents | $19.87M | $4.66M | $28.18M | $30.79M |
| Total assets | $28.71M | $10.26M | $34.75M | $48.56M |
| Total liabilities | $4.11M | $4.59M | $5.05M | $13.04M |
| Shareholders' equity | $24.60M | $5.67M | $29.71M | $35.52M |
| Return on year-end equity | -54.7% | -400.1% | -20.9% | -196.2% |
| Shares outstanding | 5.41M | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Neuphoria Therapeutics Inc. | Longeveron Inc. | China SXT Pharmaceuticals, Inc. | Vistagen Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.17M Ended 2026-06-30 | $1.20M Ended 2025-12-31 | $1.14M Ended 2026-03-31 | $1.27M Ended 2026-03-31 |
| 1 year earlier | $15.65M Ended 2025-06-30 | $2.39M Ended 2024-12-31 | $1.74M Ended 2025-03-31 | $486.0K Ended 2025-03-31 |
| 2 years earlier | n/a | $709.0K Ended 2023-12-31 | $1.93M Ended 2024-03-31 | $1.06M Ended 2024-03-31 |
| 3 years earlier | n/a | $1.22M Ended 2022-12-31 | $1.97M Ended 2023-03-31 | n/a |
| 4 years earlier | n/a | $1.31M Ended 2021-12-31 | $2.60M Ended 2022-03-31 | $1.11M Ended 2022-03-31 |